|
市場調査レポート
商品コード
1309703
インスリンポンプの世界市場規模・シェア・産業動向分析レポート:製品別、適応疾患別、流通チャネル別(小売店・オンライン薬局、病院薬局)、地域別展望と予測、2023年~2030年Global Insulin Pump Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel (Retail & Online Pharmacies, and Hospital Pharmacy), By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
インスリンポンプの世界市場規模・シェア・産業動向分析レポート:製品別、適応疾患別、流通チャネル別(小売店・オンライン薬局、病院薬局)、地域別展望と予測、2023年~2030年 |
出版日: 2023年06月30日
発行: KBV Research
ページ情報: 英文 224 Pages
納期: 即納可能
![]() |
インスリンポンプの市場規模は2030年までに95億米ドルに達すると予測され、予測期間中のCAGRは9.9%で上昇する見込みです。
KBV Cardinalのマトリックスに示された分析によると、F. Hoffmann-La Roche Ltd.が同市場におけるトップランナーです。2021年1月、F.ホフマン・ラ・ロシュ社はカナダの顧客にSiteSmartペン型注射針システムを提供するため、Montmed Inc.とパートナーシップを締結しました。この提携は、糖尿病管理を改善するというロシュの目標を支援するものです。Medtronic PLC、Aetna, Inc.、Insulet Corporationなどの企業がこの市場における主要なイノベーターです。
COVID-19の影響
COVID-19の発生はインスリンポンプ市場の拡大を妨げました。糖尿病の診断と治療の遅れ、患者のポンプ購入の遅れが一因となっています。さらに、COVID-19の大流行時には、いくつかの政府によって規制が設けられ、ポンプや消耗品の供給が中断されました。例えば、米国糖尿病協会の報告によると、パンデミックの間、ポンプやCGMを使用している糖尿病患者の15%が消耗品の補充を遅らせた。病気に対する認識と診断の高まりにより、CGMとクローズドループポンプの売上は2021年に20%増加する見込みです。市場参入企業の収益マージンは2020年に大幅に減少しました。
市場成長要因
世界の糖尿病罹患率の増加
先進国でも新興国でも、糖尿病はより一般的になりつつあります。これは、肥満や座りっぱなしのライフスタイルなど、いくつかの要素の結果です。糖尿病に関する事実と数値は、世界中の人々、家族、国家にとって糖尿病がどれほどの苦難であるかを示しています。IDFの糖尿病アトラス(2021年)によると、成人(20~79歳)の10.5%が糖尿病であり、半数近くが自分が糖尿病であることを全く知らないです。IDFの予測によると、2045年までに成人の8人に1人にあたる7億8,300万人が糖尿病を患うことになり、46%増加します。2型糖尿病は、社会経済的、人口統計的、環境的、遺伝的変数によって引き起こされ、糖尿病患者の90%以上が罹患しています。予測期間中、糖尿病患者はこれらのポンプや疾病管理の利点をより認識するようになるため、市場は上昇すると予想されます。
製品の発売と承認の増加
新興国の糖尿病患者への普及が進むにつれて、市場参入企業は技術的に改良された製品の研究開発に注力し、市場に新商品を投入することが求められています。このような研究開発イニシアチブは、MDI療法を受けている2型糖尿病患者とは対照的にポンプ療法を受けている2型糖尿病患者のグルコースコントロールの持続的な改善を実証する数多くの臨床研究によって支えられています。その結果、市場は今後数年間で成長すると予測されています。
市場抑制要因
インスリンポンプは一般的に高価
予想される期間中、市場成長はインスリンポンプの高コストによって抑制されると予想されます。従来のヘルスケアの原動力は、こうした最新のドラッグデリバリーシステムによって根底から覆され、ヘルスケア分野にも変化をもたらしています。例えば、米国糖尿病協会が2019年4月に実施した調査によると、糖尿病患者に対するインスリンポンプ療法はMDI療法よりも高額であり、その価格差は約43.5%でした。また、これらのポンプに関する自己負担額が大きいことが、患者のポンプ使用意欲を削いでいます。
製品の展望
製品別では、市場はポンプと消耗品に二分されます。2022年には、ポンプ部門が市場で最大の売上シェアを占めました。このセグメントの拡大は、先進国における糖尿病患者のポンプ使用の増加に起因しています。複数の持続グルコースモニター、毎日の注射、その他の技術と比較して、これらの製品はいくつかの利点を提供します。Tandem社幹部によれば、1型糖尿病患者におけるポンプの採用は、国内市場および国際市場の双方で牽引力を増すにつれて拡大する見込みです。
ポンプタイプの展望
ポンプタイプ別に見ると、市場はパッチ、テザー、その他に分けられます。2022年の市場では、テザー型が最も高い収益シェアを占めています。このセグメントの市場規模が大きいのは、主にクラシックポンプの信頼性と幅広い製品ラインナップによる。ポケットに入れて持ち運べる携帯性と利便性により、テザーポンプの人気が高まっています。また、モバイル機器を使って血糖値を簡単にコントロールしたり、モニターしたりすることもできます。これらの利点により、テザーポンプの需要が増加しています。
適応疾患別展望
糖尿病の適応症別では、市場は1型糖尿病と2型糖尿病に細分化されます。2型糖尿病セグメントは、2022年の市場で大きな収益シェアを獲得しました。この疾患の有病率が世界的に上昇していることから、2型糖尿病セグメントは予測期間を通じて徐々に成長すると予測されています。市場の拡大は、インスリン依存型の2型糖尿病患者数の増加や、患者がMDIからポンプや別の代替治療法に切り替えることによっても助長されるであろう。
流通チャネルの展望
流通チャネル別に見ると、市場は小売・オンライン薬局と病院薬局に二分されます。2022年には、小売&オンライン薬局セグメントが市場で最も高い売上シェアを占めました。先進国および新興国の小売店や医薬品販売店では、糖尿病管理機器やソリューションがより容易に入手可能であったため、市場のかなりの部分を占める小売店・オンライン薬局セグメントが市場を牽引しました。インターネットの利用拡大も、このニッチ分野の市場拡大に寄与しています。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が最も高い収益シェアを獲得して市場をリードしました。これは、同地域の複数の主要市場参入企業、糖尿病有病率の上昇、新しい薬物送達技術に対する社会的需要の高まりが寄与しています。インスリンポンプの普及は、可処分所得の増加と健康意識の高まりによって促されており、同地域は予測期間中も主導権を維持すると見られています。
List of Figures
The Global Insulin Pump Market size is expected to reach $9.5 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.
Asia-Pacific region widely utilizes Insulin Pumps as a sizable portion of the world's population resides in Asia Pacific, and the region's consumers are changing their eating habits, leading to an increase in the number of diabetics. Hence, Asia Pacific captured $1,090.5 million revenue in the market in 2022. Additionally, it is anticipated that in the near future, rising consumer healthcare spending, increased retail pharmacy penetration, and rising health awareness in the region will fuel the expansion of the market in Asia Pacific.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In March, 2023, Diabeloop SA entered into a partnership with Novo Nordisk to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients. Additionally, In June, 2022, SOOIL Developments Co., Ltd partnered with Diabeloop, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the Market. In January, 2021, F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc. to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management. Companies such as Medtronic PLC, Aetna, Inc., Insulet Corporation are some of the key innovators in the Market.
COVID-19 Impact
The COVID-19 outbreak hindered the market expansion for insulin pumps. Delays in diabetes diagnosis and treatment, as well as in patients' purchases of these pumps at this time, were contributing factors. Additionally, during the COVID-19 pandemic, restrictions put in place by several governments resulted in interruptions in the delivery of pumps and supplies. For example, the American Diabetes Association reports that 15% of diabetics who use pumps or CGMs delayed replenishing their supplies during the pandemic. Due to rising disease awareness & diagnosis, CGM and closed-loop pump sales showed a 20% increase in 2021. The revenue margins of the market participants significantly decreased in 2020.
Market Growth Factors
Growing incidence of diabetes globally
Both in developed and emerging nations, diabetes is becoming more common. This is a result of several elements, such as obesity and a sedentary lifestyle. Facts and numbers on diabetes indicate how much of a hardship it is for people, families, and nations worldwide. 10.5% of adults (20-79 years) have diabetes, according to the IDF Diabetes Atlas (2021), and nearly half are completely ignorant that they have the disease. According to IDF predictions, 783 million adults, or one in eight, would have diabetes by 2045, a 46% rise. Type 2 diabetes, caused by socioeconomic, demographic, environmental, and hereditary variables, affects more than 90% of diabetics. During the forecast period, the market is expected to rise due to diabetic patients being more aware of these pumps and the advantages of disease management.
Rising product launches and approvals
The market players are urged to focus on research and development of technologically improved products and introduce new items to the market as the penetration of these pumps among diabetics in emerging nations rises. These R&D initiatives have been supported by numerous clinical studies that demonstrate sustained improvement in glucose control in type 2 diabetic individuals receiving pump therapy as opposed to those receiving MDI therapy. As a result, the market is predicted to grow in the upcoming years.
Market Restraining Factors
Insulin pumps are generally expensive
During the anticipated term, market growth is expected to be constrained by the high cost of insulin pumps. The dynamics of conventional healthcare have been upended by these contemporary drug delivery systems, which have also changed the healthcare sector. For instance, a study conducted by the American Diabetes Association in April 2019 found that insulin pump therapy for diabetic patients is more expensive than MDI therapy, with a price difference of about 43.5%. Also, the greater out-of-pocket costs related to these pumps have discouraged patients from using them.
Product Outlook
On the basis of product, the market is bifurcated into pumps and consumables. In 2022, the pumps segment witnessed the largest revenue share in the market. The segment's expansion results from the diabetic population's rising use of them in industrialized nations. Compared to several continuous glucose monitors, daily injections, and other technologies, these goods provide several advantages. The adoption of pumps among patients with type 1 diabetes is expected to grow as they gain traction in both the domestic and international markets, according to senior Tandem executives.
Pumps Type Outlook
By pumps type, the market is divided into patch, tethered and others. The tethered held the highest revenue share in the market in 2022. The segment's significant market size is primarily attributable to the classic pumps' dependability and the wide range of products available. Due to their portability and convenience, that allow people to carry them in their pockets, tethered insulin pumps have grown in popularity. It may also be easily controlled and used to monitor blood glucose levels via mobile devices. These benefits have led to a rise in the demand for tethered pumps.
Disease Indication Outlook
By diabetes indication, the market is fragmented into Type 1 Diabetes, and Type 2 Diabetes. The Type 2 Diabetes segment garnered a significant revenue share in the market in 2022. Due to the rising prevalence of this condition worldwide, it is also anticipated that the type 2 diabetes segment will grow gradually throughout the course of the projected period. The market's expansion will also be aided by the rising number of type 2 diabetics who are insulin-dependent and by the patients switching from MDIs to pumps and another alternative treatment alternative.
Distribution Channel Outlook
By distribution channel, the market is bifurcated into retail & online pharmacy and hospital pharmacy. In 2022 the retail & online pharmacy segment held the highest revenue share in the market. The retail & online pharmacy segment, which had a sizable portion of the market, led because diabetic management devices &solutions were more readily available in retail & pharmaceutical outlets in developed and developing countries. The growing use of the internet also contributes to the market expansion in this niche.
Regional Outlook
Region wise, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is aided by multiple major market participants in the region, higher diabetes prevalence, and rising public demand for novel medication delivery technologies. The population's adoption of insulin pumps has been prompted by rising disposable income and health awareness, and the region is expected to maintain its leadership during the forecast period.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., Insulet Corporation, Ypsomed AG, Aetna, Inc. (CVS Pharmacy, Inc.), SOOIL Developments Co., Ltd, Diabeloop SA, Jiangsu Delfu Medical Device Co.,Ltd, and APEX Medical Corporation
Recent Strategies Deployed in Insulin Pump Market
Partnerships, Collaborations, and Agreements:
2023-Mar: Diabeloop SA entered into a partnership with Novo Nordisk, a Danish healthcare company, to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients.
2022-Nov: Ypsomed AG teamed up with CamDiab, a glucose level management solutions provider, to launch an automated insulin dosing system. The collaboration features the integration of Ypsomed's offerings with CamDiab's adaptive hybrid closed-loop app that would allow Ypsomed to better serve its diabetic patients.
2022-Jun: SOOIL Developments Co., Ltd partnered with Diabeloop, a diabetes management solutions provider, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.
2021-Nov: Diabeloop SA announced a partnership with Terumo Corporation, a medical technology company, to develop solutions for Automated Insulin Delivery. The partnership enhances Diabeloop's position in the European market and would provide its customers with better diabetes care solutions.
2021-Jan: F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc., an Insulin delivery specialist based in Canada, to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management.
Mergers & Acquisition:
2023-May: Medtronic PLC acquired EOFlow Co. Ltd., an insulin delivery solutions provider. The acquisition strengthens Medtronic's diabetes management portfolio.
2023-Feb: Insulet Corporation took over the automated insulin delivery assets of Automated Glucose Control LLC, an automated insulin delivery solution provider based in the United States. The acquisition would strengthen the company's ability to deliver automated insulin delivery technology.
2023-Feb: Insulet Corporation announced the acquisition of automated insulin delivery assets of Bigfoot Biomedical, an intelligent injection solutions provider. The acquisition enhances Insulet's IP portfolio.
2023-Jan; Tandem Diabetic Care, Inc. completed the acquisition of AMF Medical SA, an Insulin patch pump manufacturer. The acquisition would enhance the diabetes management expertise of the company by adding a well-experienced team.
Trials and Approvals:
2023-Apr: Medtronic PLC announced the approval by U.S. Food and Drug Administration (FDA) for its MiniMed 780G. The MiniMed 780G is an insulin injector system used when the consumer puts low carbs in their meal.
2023-Apr: The US FDA announced the approval for Insulet Corporation's Omnipod GO, an insulin delivery device used for the treatment of type 2 diabetes.
2022-Feb: Tandem Diabetes Care, Inc. received approval from U.S. Food and Drug Administration for its t:slim X2 insulin pump. The t:slim X2 is used to monitor glucose levels in the patient's body. Additionally, the t:slim X2 can be used along with t:connect mobile app.
Product Launches and Product Expansions:
2022-Nov: Medtronic PLC released the Medtronic Extended infusion set. The infusion set has a wear time of 7 days and uses a tubing connector that would be used for insulin stability.
2021-Mar: Roche has announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which supports and enables Roche's approach of integrated Personalized Diabetes Management (iPDM). iPDM is a holistic, patient-centered therapeutic approach with the ultimate goal of personalizing diabetes management to streamline care and improve clinical outcomes. iPDM aims to strengthen the care process, facilitates communication between patients and their healthcare team, and integrates tools that visualize and analyze data.
Geographical Expansions:
2022-Jun: Insulet Corporation expanded its geographical footprint by opening a new manufacturing facility in Johor Bahru, Malaysia. The new facility would be used for manufacturing the company's Omnipod Insulin Management System.
Market Segments covered in the Report:
By Product
By Disease Indication
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research